ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial.
June 4, 2026 07:01 AM EDT
R&DPharmaFDA+
ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
Reynald Castaneda
Deputy Editor
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
Why Is ADC Therapeutics Stock Falling Thursday? - ADC Therapeutics (NYSE:ADCT)
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions…
In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is…
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
MapLight pauses preclinical work to focus on ML-007C-MA for schizophrenia; ADC Therapeutics weighs Zynlonta's future after FDA…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory…
